Actinogen Medical LimitedASX: ACW

Application for quotation of securities - ACW

Sep 29, 2026 at 11:04 PM EDT · Issued by Actinogen Medical Limited via ASX

Filed with ASX · Sep 29, 2026 at 11:04 PM EDT

On 6ix: 6ix.com/news/application-for-quotation-of-securities-acw

Appendix 2A - Application for quotation of securitiesAppendix 2A - Application for quotation of securities1 / 6Announcement SummaryEntity nameACTINOGEN MEDICAL LIMITEDAnnouncement TypeNew announcementDate of this announcementWednesday September 30, 2026The +securities to be quoted are:Total number...

View Attachment

6ix hasn’t read this filing yet.

Actinogen Medical Limited on 6ix

Earlier from Actinogen Medical

Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for NovemberSep 23
Underwriting of unlisted options completedSep 22
Options underwriting cleansing noticeSep 22
ACW Alzheimers pivotal trial completes last patient visitSep 22
Notification of cessation of securities - ACWSep 15

Later from Actinogen Medical

AGM date and closing date for director nominationsOct 8
Notification of buy-back - ACWOct 11
ACW September 2026 quarterly activity report & Appendix 4COct 18
ACW pivotal Alzheimers trial database lock - results mid-NovOct 20
Actinogen receives $10.8m R&D tax incentive rebate from ATOOct 25

All Actinogen Medical news releases

Follow Actinogen Medical into a list and get an email when it puts out news.

Follow Actinogen Medical